State Street’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $247K | Buy |
36,222
+10,326
| +40% | +$77.3K | ﹤0.01% | 3839 |
|
|
2025
Q4 | $218K | Buy |
25,896
+10,634
| +70% | +$118K | ﹤0.01% | 3882 |
|
|
2025
Q3 | $198K | Sell |
15,262
-171
| -1% | -$2.02K | ﹤0.01% | 3920 |
|
|
2025
Q2 | $151K | Hold |
15,433
| – | – | ﹤0.01% | 3895 |
|
|
2025
Q1 | $186K | Hold |
15,433
| – | – | ﹤0.01% | 3844 |
|
|
2024
Q4 | $238K | Buy |
15,433
+1,075
| +7% | +$20.3K | ﹤0.01% | 3806 |
|
|
2024
Q3 | $331K | Sell |
14,358
-943
| -6% | -$21.1K | ﹤0.01% | 3684 |
|
|
2024
Q2 | $296K | Sell |
15,301
-43,464
| -74% | -$1.16M | ﹤0.01% | 3703 |
|
|
2024
Q1 | $2.21M | Buy |
58,765
+18,731
| +47% | +$775K | ﹤0.01% | 3246 |
|
|
2023
Q4 | $1.21M | Buy |
40,034
+438
| +1% | +$9.55K | ﹤0.01% | 3442 |
|
|
2023
Q3 | $868K | Buy |
39,596
+4,361
| +12% | +$154K | ﹤0.01% | 3564 |
|
|
2023
Q2 | $1.37M | Sell |
35,235
-44
| -0.1% | -$3.88K | ﹤0.01% | 3527 |
|
|
2023
Q1 | $3.25M | Sell |
35,279
-107,508
| -75% | -$13.5M | ﹤0.01% | 3148 |
|
|
2022
Q4 | $20.4M | Buy |
142,787
+20,395
| +17% | +$5.09M | ﹤0.01% | 2233 |
|
|
2022
Q3 | $27.8M | Buy |
122,392
+92,651
| +312% | +$23.5M | ﹤0.01% | 1989 |
|
|
2022
Q2 | $6.95M | Buy |
29,741
+4,943
| +20% | +$1.09M | ﹤0.01% | 2929 |
|
|
2022
Q1 | $7.92M | Buy |
24,798
+4,333
| +21% | +$997K | ﹤0.01% | 2945 |
|
|
2021
Q4 | $5.73M | Buy |
20,465
+1,950
| +11% | +$335K | ﹤0.01% | 3172 |
|
|
2021
Q3 | $2.32M | Buy |
18,515
+2,815
| +18% | +$349K | ﹤0.01% | 3570 |
|
|
2021
Q2 | $2.58M | Buy |
15,700
+15,043
| +2,290% | +$3.06M | ﹤0.01% | 3501 |
|
|
2021
Q1 | $137K | Sell |
657
-310
| -32% | -$71.1K | ﹤0.01% | 3878 |
|
|
2020
Q4 | $217K | Hold |
967
| – | – | ﹤0.01% | 3745 |
|
|
2020
Q3 | $184K | Hold |
967
| – | – | ﹤0.01% | 3672 |
|
|
2020
Q2 | $233K | Sell |
967
-1,853
| -66% | -$364K | ﹤0.01% | 3607 |
|
|
2020
Q1 | $325K | Sell |
2,820
-223
| -7% | -$33.1K | ﹤0.01% | 3515 |
|
|
2019
Q4 | $508K | Buy |
3,043
+804
| +36% | +$407K | ﹤0.01% | 3523 |
|
|
2019
Q3 | $2.22M | Buy |
2,239
+409
| +22% | +$457K | ﹤0.01% | 3179 |
|
|
2019
Q2 | $2.09M | Buy |
1,830
+977
| +115% | +$886K | ﹤0.01% | 3226 |
|
|
2019
Q1 | $652K | Sell |
853
-329
| -28% | -$299K | ﹤0.01% | 3412 |
|
|
2018
Q4 | $1.14M | Buy |
1,182
+19
| +2% | +$25K | ﹤0.01% | 3298 |
|
|
2018
Q3 | $1.97M | Buy |
1,163
+371
| +47% | +$484K | ﹤0.01% | 3247 |
|
|
2018
Q2 | $812K | Buy |
792
+144
| +22% | +$155K | ﹤0.01% | 3420 |
|
|
2018
Q1 | $696K | Buy |
+648
| New | +$1.19M | ﹤0.01% | 3392 |
|
Other funds holding ACET
RCM
O
VCM
WP
PM
SCM
State Street's ACET Position: Q1 2026 in Review
State Street increased its Adicet Bio (ACET) stake by 40% in Q1 2026, buying an estimated $77.3K and bringing the position to 36,222 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #3839.
State Street first reported a position in ACET in Q1 2018 and has held it in 33 quarters since. The position peaked at $27.8M in Q3 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.
- State Street held 36,222 shares of Adicet Bio worth $247K as of Q1 2026.
- State Street bought 10,326 Adicet Bio shares in Q1 2026, an estimated $77.3K.
- Adicet Bio made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3839 holding.
- State Street first reported a position in Adicet Bio in Q1 2018 and has held it in 33 quarters since.
- State Street's Adicet Bio position peaked at $27.8M in Q3 2022.
- 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.